We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Bio-Engineered Implant Helps Heal Torn ACLs

By HospiMedica International staff writers
Posted on 11 Jan 2021
A novel implant acts as a biological bridge between the two ends of a torn anterior cruciate ligament (ACL) to facilitate healing.

The Miach Orthopaedics (Westborough, MA, USA) Bridge-Enhanced ACL Repair (BEAR) implant is designed to restore natural anatomy and function of the knee. More...
The implant, which is comprised of a proprietary blend of extracellular matrix (ECM) proteins and collagen, is stitched into place during arthroscopy between the torn ends of the ACL and then injected with the patient’s blood, which clots in the implant. The BEAR is held in place long enough for the body to heal the torn ends of the ACL back together, while maintaining its original attachments to the femur and tibia. As the ACL heals, the BEAR implant is absorbed by the body, within approximately eight weeks.

Unlike surgical ACL reconstruction, which is the current standard of care, the implant does not require a second surgical wound site to remove a healthy tendon from another part of the leg, or implanting a deceased donor's tendon. The BEAR implant is indicated for skeletally mature patients at least 14 years of age with a complete rupture of the ACL, as confirmed by magnetic resonance imaging (MRI). Patients must have an ACL stump attached to the tibia to construct the repair, and the device must be implanted within 50 days of injury.

“Preserving a patient's native ACL instead of replacing it with a graft has long been a goal of surgeons, and before the BEAR implant, multiple approaches were studied and failed,” said Martha Shadan, CEO and president of Miach Orthopaedics. “The BEAR implant, which is the first medical technology to show that it enables a patient's own torn ACL to heal, represents the first substantial advancement in the treatment of ACL tears in decades, and has the potential to change the standard of care.”

The ACL is a broad, thick collagen cord that originates on the anterior portion of the femur in the intercondylar notch and inserts on the posterior aspect of the tibial plateau. The ACL guides the tibia through a normal, stable range of motion, along the end of the femur, maintaining joint stability. The ligament is unfortunately poorly vascularized, and thus has no ability to heal itself after a complete tear, leading to further destruction of the articular and meniscal cartilage over time.

Related Links:
Miach Orthopaedics


Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Electric Bed
DIXION Intensive Care Bed
Bipolar Coagulation Generator
Aesculap
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.